成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 823-78-9 Chemical Structure| 823-78-9

Structure of 823-78-9

Chemical Structure| 823-78-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 823-78-9

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Dube, Phelelisiwe S. ; Angula, Klaudia T. ; Legoabe, Lesetja J. ; Jordaan, Audrey ; Boitz Zarella, Jan M. ; Warner, Digby F. , et al.

Abstract: Herein, we describe 39 novel quinolone compounds bearing a hydrophilic amine chain and varied substituted benzyloxy units. These compounds demonstrate broad-spectrum activities against acid-fast bacterium, Gram-pos. and -neg. bacteria, fungi, and leishmania parasite. Compound 30 maintained antitubercular activity against moxifloxacin-, isoniazid-, and rifampicin-resistant Mycobacterium tuberculosis, while 37 exhibited low micromolar activities (<1 μg/mL) against World Health Organization (WHO) critical pathogens: Cryptococcus neoformans, Acinetobacter baumannii, and Pseudomonas aeruginosa. Compounds in this study are metabolically robust, demonstrating % remnant of >98% after 30 min in the presence of human, rat, and mouse liver microsomes. Several compounds thus reported here are promising leads for the treatment of diseases caused by infectious agents.

Alternative Products

Product Details of [ 823-78-9 ]

CAS No. :823-78-9
Formula : C7H6Br2
M.W : 249.93
SMILES Code : BrCC1=CC(Br)=CC=C1
MDL No. :MFCD00000176
InChI Key :ZPCJPJQUVRIILS-UHFFFAOYSA-N
Pubchem ID :69979

Safety of [ 823-78-9 ]

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H314
Precautionary Statements:P280-P305+P351+P338-P310
Class:8
UN#:3261
Packing Group:Ⅱ

Computational Chemistry of [ 823-78-9 ] Show Less

Physicochemical Properties

Num. heavy atoms 9
Num. arom. heavy atoms 6
Fraction Csp3 0.14
Num. rotatable bonds 1
Num. H-bond acceptors 0.0
Num. H-bond donors 0.0
Molar Refractivity 46.98
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

0.0 ?2

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.42
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

-2.07
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

3.19
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

3.83
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

3.53
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.18

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-0.51
Solubility 76.7 mg/ml ; 0.307 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

2.6
Solubility 98800.0 mg/ml ; 395.0 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Highly soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-4.51
Solubility 0.00771 mg/ml ; 0.0000308 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

 Low
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

 Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

 No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

 Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

 No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

 No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

 No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

 No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-9.29 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

 0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

 None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

 0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

 0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

 2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

 No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

 1.78

Application In Synthesis of [ 823-78-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 823-78-9 ]

[ 823-78-9 ] Synthesis Path-Downstream   1~13

  • 1
  • [ 823-78-9 ]
  • [ 349-58-6 ]
  • [ 741683-46-5 ]
  • 2
  • [ 823-78-9 ]
  • [ 30163-20-3 ]
  • 3
  • [ 150008-24-5 ]
  • [ 823-78-9 ]
  • [ 1229313-27-2 ]
  • 4
  • [ 823-78-9 ]
  • [ 40253-47-2 ]
  • [ 1570494-08-4 ]
YieldReaction ConditionsOperation in experiment
60% With potassium carbonate; In tetrahydrofuran; at 50℃; for 18h; To a solution of ethyl 5-methyl-lH-l,2,4-triazole-3-carboxylate (1.0 g, 6.44 mmol) and l-bromo-3-(bromomethyl)benzene (1.77 g, 7.08 mmol) in THF (32 mL), K2CO3 (1.78 g, 12.88 mmol) was added. The mixture was stirred at 50°C for 18 h, and then the reaction was filtered under vacuum. The solvent was removed under reduced pressure and the crude product was purified on a Biotage pre-packed silica gel column (EtOAc:Hexane 12percent to 100percent EtOAc) to afford ethyl l-(3- bromobenzyl)-5-methyl-lH-l,2,4-triazole-3-carboxylate (1.25 g, 60percent) as a viscous oil. MS(ES+) Ci3H14BrN302 requires: 323, 325 found: 324, 326 [M+H]+(l :l).
60% With potassium carbonate; In tetrahydrofuran; at 50℃; for 18h; To a solution of ethyl 5-methyl-lH-l,2,4-triazole-3-carboxylate (1.0 g, 6.44 mmol) and l-bromo-3-(bromomethyl)benzene (1.77 g, 7.08 mmol) in THF (32 mL), K2CO3 (1.78 g, 12.88 mmol) was added. The mixture was stirred at 50°C for 18 h then filtered. The filtrate was concentrated under reduced pressure and the crude product was purified on a Biotage pre-packed silica gel column with a gradient of 12percent to 100percent EtOAc:Hexanes to afford ethyl l-(3-bromobenzyl)-5-methyl-lH- l,2,4-triazole-3-carboxylate (1.25 g, 60percent) as a viscous oil. MS(ES+) Ci3H14BrN302 requires: 323, 325 found: 324, 326 [M+H]+(l :l).
  • 5
  • [ 823-78-9 ]
  • [ 171663-13-1 ]
  • 6
  • [ 823-78-9 ]
  • [ 122-72-5 ]
  • 7
  • [ 823-78-9 ]
  • [ 57611-47-9 ]
  • methyl (R)-1-benzyl-3-(3-bromobenzyl)-4-oxopiperidine-3-carboxylate [ No CAS ]
  • methyl (S)-1-benzyl-3-(3-bromobenzyl)-4-oxopiperidine-3-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
General procedure: To a 10 mL reaction tube was added <strong>[57611-47-9]methyl 1-benzyl-4-oxopiperidine- 3-carboxylate</strong> 2c (49.5 mg, 0.2 mmol), 50% aq. KOH (112 mg, 1 mmol, 5 eq) and phase transfer catalyst 1k (12.1 mg, 0.02 mmol, 10 mol%) followed by p-xylene (1 mL). After the mixture was stirred at rt for 30 min, BnBr (71.3 uL, 0.6 mmol, 3 eq) was added, and the stirring was continued at rt for additional 12 h (monitored by TLC analysis). The crude product was purified by column flash chromatography (eluting with 20:1 hexane/EtOAc) to afford 3c (256 mg, 76% yield) as colorless transparent liquid.
  • 8
  • [ 823-78-9 ]
  • [ 51135-91-2 ]
  • C16H14BrNO [ No CAS ]
YieldReaction ConditionsOperation in experiment
With potassium carbonate; In acetonitrile; at 85℃; General procedure: To a solution of compound 3 (<strong>[51135-91-2]4-amino-2,3-dihydro-1H-inden-1-one</strong>, 1.00 g, 1.0 equiv) and potassium carbonate (1.21 g, 1.1 equiv) in acetonitrile (35 mL) was added bromide derivative (1.1 equiv). The mixture was stirred for 3 h at 85 C. Then, the reaction was cooled to room temperature and the potassium carbonate was filtrated off and washed with saturated saline solution and ethyl acetate (3×15 mL). The combined organic phase was concentrated under vacuo and purified on a silica gel chromatography to give corresponding target product (b1-b6).
  • 9
  • [ 823-78-9 ]
  • [ 364794-80-9 ]
  • 10
  • [ 4803-74-1 ]
  • [ 823-78-9 ]
  • 1-(3-bromobenzyl)-4-[(5,6-dimethoxy-1-indanone-2-ylidene)methyl]pyridinium bromide [ No CAS ]
YieldReaction ConditionsOperation in experiment
64% In acetonitrile; at 80℃; for 48h; General procedure: 5,6-Dimethoxy-2-[(pyridin-4-yl)methylene)-1-indanone (0.35 mmol) was dissolved in 4 cc acetone (for synthesis of 5a) or acetonitrile (for synthesis of 5b-o) under refux temperature, and then 1.05 mmol of appropriate alkyl halides was added. The reaction mixture was stirred for 48 h under refux condition. The precipitate was fltered and washed with appropriate solvent. The obtained solid was dried under reduced pressure to aford related compounds.
  • 11
  • [ 823-78-9 ]
  • [ 436-77-1 ]
  • C58H57Br3N2O6(2+)*2Br(1-) [ No CAS ]
YieldReaction ConditionsOperation in experiment
General procedure: The mixture of stirred DTET (100 mg, 0.16 mmol) and NaH (20 mg,0.83 mmol) was dissolved in 2 mL DMF at 0 C. Then, R1Br (0.5 mmol)dissolved in 0.5 mL DMF was added to the DTET solution, and themixture was stirred at 0 C for 6 h, then heated to 92 C until the TLCanalysis showed that the reaction was completed. The temperature ofthe mixture was cooled to room temperature and vacuum evaporated.The residue was purified using aluminum column chromatography, and4a-4 h were obtained using CH2Cl 2/CH3OH as the eluent.
  • 12
  • [ 823-78-9 ]
  • [ 436-77-1 ]
  • C44H45BrN2O6 [ No CAS ]
YieldReaction ConditionsOperation in experiment
93.1% General procedure: The mixture of stirred DTET (100 mg, 0.16 mmol) and NaH (20 mg,0.83 mmol) was dissolved in 2 mL DMF at 0 C. Then, R1Br (0.18 mmol)dissolved in 0.5 mL DMF was added to the DTET solution, and themixture was stirred until the TLC analysis showed that the reaction wascompleted. The temperature of the mixture was cooled to room temperatureand vacuum evaporated. The residue was purified using aluminumcolumn chromatography, and 3a-3m were obtained usingCH2Cl2/CH3OH as the eluent
 

Related Products

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 823-78-9 ]

Aryls

Chemical Structure| 589-15-1

A523470 [589-15-1]

1-Bromo-4-(bromomethyl)benzene

Similarity: 1.00

Chemical Structure| 27561-51-9

A698441 [27561-51-9]

1-Bromo-4-(bromomethyl)-2-methylbenzene

Similarity: 0.97

Chemical Structure| 259231-26-0

A509136 [259231-26-0]

2-Bromo-4-(bromomethyl)-1-methylbenzene

Similarity: 0.97

Chemical Structure| 69189-19-1

A940641 [69189-19-1]

4-Bromo-1,2-bis(bromomethyl)benzene

Similarity: 0.93

Chemical Structure| 56908-88-4

A877740 [56908-88-4]

1,3-Dibromo-5-(bromomethyl)benzene

Similarity: 0.93

Bromides

Chemical Structure| 589-15-1

A523470 [589-15-1]

1-Bromo-4-(bromomethyl)benzene

Similarity: 1.00

Chemical Structure| 27561-51-9

A698441 [27561-51-9]

1-Bromo-4-(bromomethyl)-2-methylbenzene

Similarity: 0.97

Chemical Structure| 259231-26-0

A509136 [259231-26-0]

2-Bromo-4-(bromomethyl)-1-methylbenzene

Similarity: 0.97

Chemical Structure| 69189-19-1

A940641 [69189-19-1]

4-Bromo-1,2-bis(bromomethyl)benzene

Similarity: 0.93

Chemical Structure| 56908-88-4

A877740 [56908-88-4]

1,3-Dibromo-5-(bromomethyl)benzene

Similarity: 0.93

Benzyl Bromides

Chemical Structure| 589-15-1

A523470 [589-15-1]

1-Bromo-4-(bromomethyl)benzene

Similarity: 1.00

Chemical Structure| 27561-51-9

A698441 [27561-51-9]

1-Bromo-4-(bromomethyl)-2-methylbenzene

Similarity: 0.97

Chemical Structure| 259231-26-0

A509136 [259231-26-0]

2-Bromo-4-(bromomethyl)-1-methylbenzene

Similarity: 0.97

Chemical Structure| 69189-19-1

A940641 [69189-19-1]

4-Bromo-1,2-bis(bromomethyl)benzene

Similarity: 0.93

Chemical Structure| 56908-88-4

A877740 [56908-88-4]

1,3-Dibromo-5-(bromomethyl)benzene

Similarity: 0.93